IDH2 and acute myeloid leukemia: Treatment consisting of the single agent, Enasidenib, resulted in a CR of 19.6% and an overall response rate (ORR) of 38.8% with a median OS of 8.8 months in R/R IDH2-mutated AML (17, 133).